Background: A significant public health concern, both preventable and treatable, is chronic pulmonary obstructive disorders (Chronic obstructive pulmonary disease [COPD]). It is one of the primary causes of chronic illness and mortality worldwide. The prominent safety concerns in the use of theophylline need to be addressed.
Aim and Objective: In Grade 12 COPD patients, the efficacy and effectiveness of oral doxofylline should be contrasted with theophylline.
Materials and Methods: Two groups of 25 patients, with one group getting theophylline and the other doxofylline, were randomized to a total of 50 patients in addition to the normal treatment for 12 weeks. Each patient was accompanied by a pulmonary function test (PFT), a COPD assessment test (CAT) evaluation questionnaire, and a drug-related safety review at 6 weeks and 12 weeks for the assessment of efficacy parameters.
Results: At 6 weeks and 12 weeks within their respective classes, theophylline and doxofylline showed substantial increases in PFT and CAT performance. However, there was no noticeable change relative to the two classes. In theophylline group, the amount of adverse drug reactions is larger relative to patients in the doxofylline community. Dyspnea was the most severe harmful effect of all categories.
Conclusion: Doxofylline is also useful in treating Grade 12 COPD (global obstructive lung disease criteria), which has a greater safety profile relative to theophylline.
Key words: Doxofylline; Chronic Pulmonary Obstructive Disease; Chronic Obstructive Pulmonary Disease; Theophylline
|
